P38 MAPK and glucocorticoid receptor crosstalk in bronchial epithelial cells

Simon Lea 1 · Jian Li 1 · Jonathan Plumb 1 · Kate Gaffey 1 · Sarah Mason 1 · Rosie Gaskell 1 · Chris Harbron 2 · Dave Singh 1

Received: 12 July 2019 / Revised: 6 December 2019 / Accepted: 6 January 2020 / Published online: 23 January 2020
© The Author(s) 2020

Abstract
p38 MAPK inhibition may have additive and synergistic anti-inflammatory effects when used with corticosteroids. We investigated crosstalk between p38 MAPK inhibitors and corticosteroids in bronchial epithelial cells to investigate synergistic effects on cytokine production and the molecular mechanisms involved. Effects of the p38 MAPK inhibitor BIRB-796 and dexamethasone alone and in combination on LPS, polyI:C or TNF-α-induced IL-6, CXCL8 and RANTES were assessed in 16HBEs (human epithelial cell line) and on TNF-α-induced IL-6 and CXCL8 in primary human epithelial cells from asthma patients and healthy controls. 16HBEs were used to assess effects of BIRB-796 alone and in combination with dexamethasone on glucocorticoid receptor (GR) activity by reporter gene assay, expression of GR target genes and nuclear localisation using Western blot. The effects of BIRB-796 on TNF-α stimulated phosphorylation of p38 MAPK and GR at serine (S) 226 by Western blot. Epithelial levels of phosphorylated p38 MAPK and GR S226 were determined by immunohistochemistry in bronchial biopsies from asthma patients and healthy controls. BIRB-796 in combination with dexamethasone increased inhibition of cytokine production in a synergistic manner. Combination treatment significantly increased GR nuclear localisation compared to dexamethasone alone. BIRB-796 inhibited TNF-α-induced p38 MAPK and GR S226 phosphorylation. Phosphorylated GR S226 and p38 MAPK levels were increased in bronchial epithelium of more severe asthma patients. Molecular crosstalk exists between p38 MAPK activation and GR function in human bronchial epithelial cells, which alters GR activity. Combining a p38 MAPK inhibitor and a corticosteroid may demonstrate therapeutic potential in severe asthma.

Key messages
• Combination of corticosteroid and p38 inhibitor in human bronchial epithelial cells
• Combination increased cytokine inhibition synergistically and nuclear GR
• p38 MAPK inhibition reduced TNF-α-induced phosphorylation of GR at S226 but not S211
• Phosphorylated GRS226 and p38 is increased in bronchial epithelium in severe asthma
• Combining a p38 inhibitor and a corticosteroid may be effective in asthma treatment

Keywords Corticosteroid insensitivity · Glucocorticoid receptor · p38 MAPK · Asthma · Bronchial epithelial cells

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00109-020-01873-3) contains supplementary material, which is available to authorized users.

Abbreviations
ANOVA Analysis of variance
ACQ Asthma control questionnaire
CXCL The chemokine (C-X-C motif) ligand
DUSP1 Dual-specificity phosphatase-1
ELISA Enzyme-linked immunosorbent assays
ERK Extracellular-regulated kinase
FEV1 Forced expiratory volume in 1 s
FKBP5 FK506-binding protein 51
GILZ Glucocorticoid-induced leucine zipper
GINA Global Initiative for Asthma

1 University of Manchester, NIHR Translational Research Facility, University Hospital of South Manchester, Manchester M23 9LT, UK
2 Roche Pharmaceuticals, 6 Falcon Way, Welwyn Garden City AL7 1TW, UK
Introduction

Inhaled corticosteroids (ICS) are the mainstay of anti-inflammatory treatment for asthma. However, many asthma patients treated with ICS have suboptimal asthma control [1], highlighting the need for novel anti-inflammatory treatments.

The glucocorticoid receptor (GR) is a ligand-dependent transcription factor that resides in the cytoplasm until ligand binding causes nuclear translocation, resulting in transrepression or transactivation of gene transcription [2]. There are numerous phosphorylation sites within the GR N-terminus, changes in which can lead to the alterations of GR function through ligand binding, nuclear localisation, modulating interactions with co-regulators or transcriptional activation [3, 4]. Two such phosphorylation sites are serine (S) 211 and S226 which have roles in subcellular localisation [3]; GR-ligand nuclear translocation is associated with phosphorylation of S211, while GR nuclear export is associated with S226 phosphorylation.

p38 mitogen-activated protein kinase (MAPK) signalling promotes the secretion of inflammatory proteins through transcription factor activation [5], post-transcriptional mRNA stabilization and enhancement of protein translation [6, 7]. p38 MAPK inhibitors suppress the inflammatory responses of various cell types within the lung, including alveolar macrophages, lung lymphocytes, airway smooth muscle cells and bronchial epithelial cells [8–10]. Combining p38 MAPK inhibitors and corticosteroids results in additive anti-inflammatory effects in these cell models, due to the different mechanisms of action [8, 11]. Furthermore, these studies have also shown some evidence that the combination effects are more than additive, with a synergistic interaction observed [8, 11].

Methods

Human bronchial epithelial cell culture

The human bronchial epithelial cell line 16HBE14o− (ATCC; HPEC) was maintained in supplemented Minimal Essential Medium Eagle (MEME, Gibco, Fisher Scientific UK Ltd., Loughborough, UK). Confluent cells were grown in tissue culture plates until confluent and then incubated in fresh supplemented media in the presence of either lipopolysaccharide (LPS) (1 μg/ml, Sigma, Poole, UK), polyinosinic:polycytidylic acid (poly I:C) (100 μg/ml, Source Bioscience, Nottingham, UK) or tumour necrosis factor (TNFα) (10 ng/ml, Peprotech, London, UK). Cells were
measurement of forced expiratory volume in 1 s (FEV\textsubscript{1}) and/or the p38 MAPK inhibitor BIRB-796 (0.1–1000 nM, Sigma) and/or the p38 MAPK inhibitor BIRB-796 (0.1–1000 nM, Sigma) and incubated in 5% CO\textsubscript{2} at 37 °C for varying time points. Plates were centrifuged at 2000 rpm for 10 min at 4°C and cell-free supernatants removed and stored at −80°C for cytokine analysis.

To assess the effects of LPS, poly I:C and TNFα stimulation on phosphorylated p38 MAPK expression, HBECs were stimulated with LPS (1 μg/ml) or poly I:C (100 μg/ml) for 0–180 min or with TNFα (10 ng/ml) for 0–60 min.

To assess the effects of dexamethasone and BIRB-796 on stimulated phosphorylated p38 MAPK expression, HBECs were pre-incubated for 60 min with both dexamethasone (1000 nM), BIRB-796 alone (1000 nM) or both in combination, followed by stimulation with LPS (1 μg/ml) or poly I:C (100 μg/ml) for 60 min or with TNFα (10 ng/ml) for 15 min (based on preliminary time course experiments; Fig. S1).

To assess the effects of dexamethasone and BIRB-796 on GR target gene expression, HBECs were cultured with or without TNFα (10 ng/ml) for 15 min followed by dexamethasone (100 nM) and BIRB-796 (100 nM) both alone and in combination for 4 h.

To investigate the effects of dexamethasone on GR phosphorylation at S211 and S226 residues, HBECs were incubated with dexamethasone (1000 nM) or left untreated for 15–180 min.

To assess whether TNFα-induced phosphorylation of GR S226 is p38 MAPK-dependent, HBECs were stimulated with TNFα (10 ng/ml) for 15–180 min with and without pre-incubation of BIRB-796 (1000 nM) for 60 min.

**Study subjects**

Patients with a diagnosis of asthma (n = 23) and healthy control subjects (n = 15) were recruited; all subjects were required to be lifelong non-smokers. Patients performed spirometry for measurement of forced expiratory volume in 1 s (FEV\textsubscript{1}) and reversibility to inhaled salbutamol (200 μg), asthma control questionnaire (ACQ), and skin prick testing using house dust mite, cat and grass allergens (Soluprick SQ, Alk Abelló (UK) Ltd). The study was approved by the local research ethics committee (NRES Committee North West – Greater Manchester South; REC Ref: 06/Q1403/156). All subjects provided written informed consent.

**Bronchoscopy**

Patients with differing asthma severity as defined by the Global Initiative for Asthma (GINA) score (GINA 1, n = 5; GINA 2, n = 7; and GINA 3/4, n = 6) and healthy control subjects (n = 10) underwent bronchoscopy to obtain bronchial biopsies from the lower lobes; these were formalin-fixed and paraffin-embedded as previously described [24]. Asthma patients (n = 5) and healthy control subjects (n = 5) underwent bronchoscopy to obtain brushings from the lower lobe segmental airways.

**Primary epithelial cell culture**

Bronchial epithelial cells obtained from asthma patients and healthy controls were gently removed from the airway by brushing with a cytology brush (width 5 mm, length 10 mm) (Olympus, Southend-on-sea, UK) across the surface of the airway wall. Cells were then placed into fully supplemented BEBM Media (BEBM bulletkit Lonza, Slough, UK) on ice by passing the sheath over the head of the brush to dislodge cells. Cells were centrifuged (400 g, 10 min, 4°C) before resuspending into supplemented BEBM media. The whole cell suspension was seeded into collagen-coated (Nutacon, Leimuiden, Netherlands) flasks. Cells were left to adhere and grow and media was replaced twice weekly. When confluent, cells were passaged and plated out into 96-well plates. When 80% confluence was reached, cells were pre-incubated for 60 min with either dexamethasone (100 nM), BIRB-796 (100 nM) or both drugs in combination before stimulation with TNFα (10 ng/ml) for 24 h.

**Cytokine measurements**

Enzyme-linked immunosorbert assays (ELISA) were used to determine the supernatant level of Interleukin (IL)-6, the chemokine (C-X-C motif) ligand 8 (CXCL8), and Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) according to the manufacturer’s instructions (R&D Systems, Abingdon, UK). Lower limits of quantification were 32.5 pg/ml for CXCL8 and RANTES and 9.375 pg/ml for IL-6.

**Western blot**

Western blot analysis was performed using the following antibodies: phospho-p38 MAPK (New England Biolabs, Hitchin, UK), total p38 MAPK (New England Biolabs), phospho-GR S226 (Abcam, Cambridge, UK), phospho-GR S211 (New England Biolabs), total GR (BD bioscience), β-actin (Abcam) and histone-3 (Cell Signalling Technology, MA, USA) (for full details, see the online supplement). All Western blot protein molecular weights are shown in Fig. S2a. HBECs were lysed for either whole cell lysate or cellular fractions (see online supplement). Nuclear and cytoplasmic fractions were confirmed in

patients (n = 5) and healthy control subjects (n = 5) underwent bronchoscopy to obtain brushings from the lower lobe segmental airways.
GR- reporter gene assay

16HBE14o- cells were stably transfected with pGL4.436[luc2P/MMTV/Hygro] vector (Promega) (Sall linearized) using FuGENE6 (Roche, Germany) (as described in online supplement).

Cells with luciferase reporters were treated with dexamethasone, BIRB-796, SB239063, budesonide and TNFα, either individually or in combination. Bioluminescence signals were analysed in BRASS software and RAP algorithm. Data were presented as photon counts per minute (cpm).

GR target gene PCR

RNA was obtained as described in the online supplement. Gene expression was analysed using TaqMan gene expression assays for GLIZ, FKBP5 and the endogenous control glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Relative expression levels compared to unstimulated controls were determined using the 2^ΔΔCt method. Full details are described in online supplement.

Immunohistochemistry

Bronchial biopsies were stained with rabbit antihuman GR S226 (Abcam, Cambridge, UK) and rabbit antihuman phosphorylated p38 MAPK (Cell Signalling Technology) coupled with an ImmPRESS™ Excel Amplified HRP Polymer Staining Kit (Anti-Rabbit IgG) with 3,3’ dianinobenzidine as a substrate (Vector Laboratories, CA, USA). Sections were counterstained in Gills haematoxylin (for full details, see the online supplement).

Images were captured using a Nikon Eclipse 80i microscope (Nikon UK Ltd) with an attached QImaging digital camera (Media Cybernetics, MD, USA). Percentages of GR S226- and phosphorylated p38 MAPK-positive epithelial cells were calculated.

Data analysis

The data and statistical analyses comply with the recommendations on experimental design and analysis in pharmacology [25].

One-way analysis of variance (ANOVA) followed by Tukey-Kramer multiple comparisons tests was used for ELISA and immunohistochemistry data to compare between conditions and subject groups. Pearson’s rank was used to assess correlations between phosphorylated p38 MAPK and GR S226 expression. Repeated measures ANOVA with Dunnett multiple comparisons post-test were used to analyse immunofluorescence and Western blot analysis. Maximal inhibition was defined as the effect of the drug at the highest concentration. IC50 values were determined using a four-parameter non-linear iterative curve fitting analysis. A dose-sparing analysis to assess whether equivalent responses can be achieved at lower doses of compound than expected given the monotherapy responses and an efficacy-enhancing analysis to assess whether the combination results in a significantly greater maximal effect than either compound as monotherapies were performed [26] and described in full in the online supplement. To assess whether combination treatment in primary epithelial experiments had an additive or synergistic effect, an interaction ratio (IR) was calculated based on observed and expected inhibitions [27]. All statistical analysis was performed in GraphPad Prism (GraphPad Software, http://www.graphpad.com). P < 0.05 was considered significant.

Results

Inhibition of cytokine production from HBECs

The stimulation of HBECs by LPS, poly I:C and TNFα significantly increased secretion of IL-6, CXCL8 and RANTES; (p < 0.05 for all comparisons of stimulated against unstimulated levels; Fig. S3). LPS-, poly I:C- and TNFα-stimulated cytokine secretion was significantly reduced by dexamethasone or BIRB-796 in a concentration-dependent manner (Fig. S3). Differences in the magnitude of maximal inhibition (i.e., inhibition at 1000 nM) between cytokines were observed. For example, the maximal inhibition of LPS- and TNFα-stimulated IL-6 production was greater than RANTES and CXCL8 secretion (p < 0.05 for all comparisons; described further in the online supplement and in Table S1). The maximal inhibition caused by BIRB-796 and dexamethasone was generally similar, with any differences described online (Table S1).

Using BIRB-796 in combination with dexamethasone generally provided greater inhibition of LPS-, poly I:C- or TNFα-induced cytokine production compared with either drug alone (Fig. 1a-i). The maximum inhibition of cytokine production using the highest concentration of dexamethasone in combination with BIRB-796 was significantly greater compared to either drug alone for many experimental conditions (analysis presented in Table S2).

Figure 2a shows dose-sparing analysis to assess whether equivalent responses can be achieved at lower doses of compound than expected given the monotherapy responses. A dose-sparing combination index where the entirety of the 95% confidence interval lies below one (Fig. 2a) indicates a significant synergistic effect. Figure 2b shows an efficacy-enhancing analysis to assess whether the combination results in a significantly greater maximal effect than either compound as monotherapies. An efficacy-enhancing benefit where the entirety of the 95% confidence interval lies above zero (Fig. 2b) indicates a significant synergistic effect. A
combination treatment showed a significant synergistic dose-sparing effect on LPS-induced IL-6, poly I:C-induced CXCL8 and TNFα-induced CXCL8. There was a significant synergistic efficacy-enhancing benefit for LPS-induced IL-6 and RANTES and TNFα-induced IL-6 and CXCL8.

We next investigated whether these synergistic effects were due to p38 MAPK modulation of glucocorticoid receptor activity. Therefore, we investigated the effects of p38 MAPK inhibition on GR activity, cellular location and phosphorylation status.

**Effects of p38 MAPK inhibition on corticosteroid-induced GR reporter activity**

Dexamethasone (1–100 nM) and budesonide (1–100 nM) significantly induced GR-reporter activity above the untreated controls (p < 0.05) (Fig. 3a-c and Fig. S4, respectively). There was no effect of BIRB-796 in combination with either corticosteroid except for budesonide 1 nM combined with BIRB-796 (1000 nM) which significantly increased GR-reporter activity above budesonide alone (p < 0.05) (Fig. 3e). SB239063 (1000 nM) had no effect in combination with dexamethasone (Fig. S4).

TNFα (10 ng/ml) stimulation caused a small increase in GR-reporter activity. Dexamethasone (1–100 nM) and budesonide (1–100 nM) caused large increases in GR-reporter activity in TNFα-stimulated cells (p < 0.05 for all comparisons), with the addition of BIRB-796 or SB239063 causing further significant upregulation of GR-reporter activity compared to corticosteroid alone (p < 0.05 for all comparisons).

**Effects of p38 MAPK inhibition on corticosteroid-induced GR target genes**

To determine if increased GR activity observed translated to increased induction of GR target genes, the effects of combination treatment of BIRB-796 and dexamethasone on GILZ and FKBP5 were assessed.
Dexamethasone (100 nM) significantly induced GILZ and FKBP5 expression above the level of untreated controls ($p < 0.05$) (Fig. 3d and e). There was no effect of BIRB-796 in combination with dexamethasone. TNFα (10 ng/ml) stimulation or BIRB-796 treatment alone had no effect on GILZ or FKBP5 expression. Dexamethasone (100 nM) also caused increases in GILZ and FKBP5 expression in TNFα stimulated cells ($p < 0.05$ for all comparisons), with the addition of BIRB-796 causing further significant upregulation of GILZ expression compared to corticosteroid alone ($p < 0.05$ for all comparisons).

**GR nuclear localisation**

The effects of p38 MAPK inhibition on GR cellular location were investigated by Western blot analysis, which confirmed that dexamethasone (1000 nM) significantly reduced GR cytoplasmic protein levels and significantly increased nuclear GR levels compared with untreated controls ($p < 0.05$ for both comparisons; Fig. 4). Dexamethasone (0.1 nM) alone and BIRB-796 (1000 nM) alone had no effect on GR levels in either cellular compartment compared with untreated controls. Combining dexamethasone (0.1 nM) with BIRB-796 (1000 nM) reduced cytoplasmic GR and significantly increased nuclear GR levels compared with untreated controls ($p < 0.05$ both comparisons) (Fig. 4).

**Effects of p38 MAPK inhibition on corticosteroid-induced GR phosphorylation**

The effects of p38 MAPK inhibition on GR phosphorylation status were investigated by Western blot. The phosphorylation of GR S226 and GR S211 by dexamethasone administered alone was confirmed, with a relatively larger increase in GRS211 phosphorylation observed (Fig. 5a and b respectively).

LPS, poly I:C or TNFα caused phosphorylation of p38 MAPK in HBECs, which was inhibited by BIRB-796 but not by dexamethasone (Fig. S5). TNFα was used to further investigate the effects of BIRB-796 inhibition on p38 MAPK and GR phosphorylation. TNFα stimulation for 15 min significantly increased phosphorylation of p38 MAPK (15–120 min) and GR S226 above basal levels but had no effect on GR S211 phosphorylation (Fig. 5c-e). Pre-incubation with BIRB-796 significantly reduced basal and TNFα-induced (15–180 min) p38 MAPK phosphorylation. Pre-incubation with BIRB-796 also significantly reduced TNFα-induced (15 mins) GR S226 phosphorylation (Fig. 5c and d, respectively) but had no effect on phosphorylated GR S211 levels (Fig. 5e).
Combination effects of dexamethasone and BIRB-796 in primary bronchial epithelial cells

Next, we sought to confirm our findings using primary bronchial epithelial cells from both asthma patients and control subjects. Two of the five asthma patients were treated with inhaled corticosteroids. The mean FEV₁ was 72.8% predicted with mean ACQ 1.74, indicating suboptimal asthma control; see Table 1 for demographics.

TNFα induced a robust cytokine response in HBECs and so was chosen as the stimulus for primary bronchial epithelial cells; TNFα significantly increased secretion of IL-6 and CXCL8 from both healthy subjects and asthma patients ($p < 0.05$ for all comparisons; Fig. 6). Dexamethasone (100 nM) alone and BIRB-796 (100 nM) alone did not significantly inhibit IL-6 release in either asthma patients or controls (Fig. 6). Dexamethasone (100 nM) alone significantly inhibited CXCL8 in asthma patients, BIRB-796 (100 nM) alone significantly inhibited CXCL8 in both asthma patients and controls. Dexamethasone in combination with BIRB-796 caused significant inhibition of IL-6 and CXCL8 in both asthma patients and controls ($p < 0.05$ both comparisons) with inhibition significantly increased above dexamethasone alone in both groups for IL-6 but not CXCL8.

As no differences in drug effects were observed between subject groups (Fig. S6), data were pooled to give additional power for an exploratory IR analysis (Fig. 6c and f). Combination treatment provided significantly greater inhibition of IL-6 than observed with either drug alone ($p < 0.05$). IR calculation for the combination of dexamethasone and BIRB-796 predicted a 34.5% inhibition of IL-6 due to additive anti-inflammatory effects, while the observed effect was
44.3% with an IR of 1.28, falling short of the 1.5 required to demonstrate a synergistic interaction. BIRB-796 alone and in combination with dexamethasone caused significant CXCL8 inhibition that was similar in magnitude.

Expression of phosphorylated p38 MAPK and GR S226 in bronchial epithelium of asthma

Bronchial biopsies from healthy controls and asthma patients were analysed. Asthma patients were categorized as GINA 1 (no ICS use), GINA 2 (ICS low dose) and GINA 3/4 (ICS plus long-acting beta agonist treatment); demographics are shown in Table 1. The percentage of bronchial epithelial cells positively stained for both phosphorylated p38 MAPK and phosphorylated GR at S226 was significantly higher in GINA 3/4 asthma patients compared with healthy controls (p < 0.05) and compared with GINA 1 for GR S226 (p < 0.05). There was no significant difference in the percentage of epithelial staining between healthy controls and GINA 1 or GINA 2 for either phosphorylated p38 MAPK or GR. There was also a significant correlation between percentage positive staining for phosphorylated p38 MAPK and GR S226 in the whole study population (R² = 0.25, p < 0.05; Fig. 7i).

Discussion

Combining a corticosteroid and a p38 MAPK inhibitor in a HBEC line caused increased inhibition of inflammatory mediator release in a synergistic manner for both dose-sparing and efficacy-enhancing effects. This synergy was observed in some, but not all, experimental conditions, varying with the stimulus used and cytokine measured. GR reporter and GR target gene experiments demonstrated an enhancement of GR activity by p38 MAPK inhibition in TNFα-stimulated epithelial cells. Furthermore, p38 MAPK inhibition enhanced corticosteroid-induced GR nuclear localisation. Previous studies have investigated the crosstalk between p38 MAPK and GR function [8, 15, 16, 19], showing that the nature of this crosstalk appears to vary between cell types, but the mechanism of crosstalk in bronchial epithelial cells has not been studied. Focusing on human bronchial epithelial cells, our key findings are that p38 MAPK inhibition enhances GR function, demonstrated through inhibition of inflammatory cytokines, GR reporter activity, GR target gene experiments and GR nuclear localisation.

We observed that p38 MAPK inhibition reduced TNFα-induced phosphorylation of GR at S226 but not S211. We also demonstrated GINA 3/4 asthma patients had higher expression levels of both p38 MAPK and GR S226.
phosphorylation in the bronchial epithelium compared with mild asthma patients and healthy controls. High bronchial epithelial p38 MAPK phosphorylation levels have been previously reported in severe asthma [23]; We have confirmed these findings and show an association with phosphorylated GR S226 expression levels. This association in asthma patients, together with our experiments that demonstrated a role for p38 MAPK in GR S226 phosphorylation, implicates p38 MAPK activation as a mechanism that can modulate GR activity in asthma.

![Graphs showing effect of dexamethasone or TNFα with/without p38 MAPK inhibition on phosphorylation of p38 MAPK and GR at S226 and S211.](image)

Table 1  Subject demography

| Clinical characteristics | Immunohistochemistry | Bronchial brushes |
|--------------------------|----------------------|------------------|
|                          | Healthy (n = 10)     | Asthma (n = 5)   | P value |
| Gender/Male/Female       | 5/5                  | 4/1              |
| Age                      | 27 (20–37)           | 48 (41–63)       |
| ICS users                | 0/10                 | 0/6              |
| Daily ICS dose (mcg)     | 0 (0)                | 0 (0)            |
| LABA users               | 0/10                 | 0/6              |
| Atopy                    | 0/10                 | 0/6              |
| FEV₁ % predicted (%)    | 97±10.4              | 87.7±8.9         |
| Reversibility (mls)      | 273±145              | 411±232          |
| Reversibility (%)        | 4.78±2.12            | 9.45±6.58        |
| ACQ-7 Score              | N/A                  | 0.86±0.15        |

Data are presented as means ± SD, median (range) for age. Asthma control questionnaire (ACQ), forced expiratory volume (FEV₁), inhaled corticosteroids (ICS), long acting beta agonists (LABA)

a Beclometasone equivalent dose
The downstream implications of the increased phosphorylated p38 MAPK observed in asthma epithelium were investigated by the GR reporter assay and GR target gene experiments to determine the effects of p38 MAPK on GR activity. TNFα stimulation activated p38 MAPK; pharmacological inhibition of this TNFα-induced p38 MAPK activation led to enhanced GR activity. This effect was confirmed using different corticosteroids and p38 MAPK inhibitors. While the use of these additional drugs were limited to the GR reporter assay, it would be of interest to investigate their effects in other assays, for example, including the effects of budesonide in combination with a p38 MAPK inhibitor in primary cells. However, our data suggest that the crosstalk observed is a class effect.

Our data show that the GR reporter responds to TNFα alone. The reporter used is widely accepted as a reporter for GR signalling [28, 29]; however, the promoter can be activated by androgen receptor (AR) as well as glucocorticoid receptor. TNFα can induce AR expression, and there is a crosstalk between NFκB and AR signalling at genome level in mammalian cells [30, 31]. It is possible that the reporter responded to TNFα signalling through AR and not GR. The level of induction of the reporter activity by TNFα alone is however much smaller (10%–15%) compared to that induced by dexamethasone (approximately 500%). Also, we did not observe an increase in the expression of the GR target genes GILZ or FKBP5 above controls in response to TNFα alone.

Corticosteroid and p38 MAPK inhibitor effects on cytokine production from HBECs varied according to the stimulant used and the cytokine measured. Such differences have also been observed in PBMCs and alveolar macrophages [8, 11, 32–36]. This is due to differences in the signalling pathways activated by different stimuli; these pathways may show varying degrees of sensitivity to different drugs. The effects of high corticosteroid concentrations often provided only approximately 50%–70% inhibition of cytokine production. Consistent with our data, other publications, using epithelial cell lines or bronchial epithelial cells obtained by bronchoscopy, have also shown that corticosteroids have either a limited or no effect on inflammatory mediator release [37–39].

In the combination experiments, we frequently observed an additive effect, and the statistical analysis demonstrated a synergistic interaction between the corticosteroid and p38 MAPK inhibitor for some experimental conditions. The use of full dose-response curves allowed analysis of efficacy enhancement and dose-sparing effects to uncover these synergistic effects. This concurs with our previous data in alveolar
macrophages from COPD and asthma patients [8, 11] and in bronchial epithelial cells [38], showing synergy using full dose-response curves.

An additive anti-inflammatory effect was observed with combination treatment in bronchial epithelial cells obtained by bronchoscopy. The lower cell number availability compared with using a cell line meant that we were unable to construct full dose-response curves, which represent the optimum way to analyse for additive or synergistic interactions [8, 11]. This analysis was performed on samples from asthma patients pooled with healthy controls to give additional statistical power. We observed no differences in the drug effects between the two groups, although it has been shown that other cell types from asthma patients can be corticosteroid resistant [19, 21, 22]. It would also be interesting to assess the effects of a p38 MAPK inhibitor on cells with asthma who have been treated with ICS compared to steroid naïve asthmatics or healthy controls. The dexamethasone and BIRB-796 concentration used in the primary cells (100 nM) was selected as it was a suboptimal concentration in HBEC experiments on cytokine suppression, thus allowing possible pharmacological addition and synergy to be studied in combination experiments. The primary cells appeared to be less corticosteroid sensitive compared to HBECs, supporting our decision to use a relatively high but suboptimal concentration. Nevertheless, these experiments using cells from asthma patients confirm the potential anti-inflammatory advantages of combining these drug classes, with an additive effect observed on IL-6 production.

While in the present study all inflammatory mediators measured were reduced by glucocorticoids, other studies have shown increased expression of many inflammatory genes

Fig. 7 Expression of phosphorylated p38 MAPK and GR S226 in the bronchial epithelium of patients with asthma and healthy controls. Expression of phosphorylated p38 MAPK and GR at S226 was examined by immunohistochemistry in bronchial biopsy tissue from healthy subjects (n = 10) and asthma patients of differing severity (GINA 1, n = 5; GINA 2, n = 7; GINA 3/4, n = 6). Representative images are shown for healthy subjects (HNS) (a and d) and GINA3/4 (b and e) for phospho-p38 MAPK (a and b) and phospho-GR S226 (d and e), negative controls for p38 MAPK and GR S226 (c and f, respectively). Red arrows indicate negative cells within epithelium. Data presented as positive cells per mm of epithelium for phospho-p38 MAPK (g) and phospho-GR S226 (h) and both (i). Data represents individual patients with mean (g and h) and linear regression (i). * = significant between groups (p < 0.05).
such as TLR2 or interferon regulatory factor 1 (IRF1) and CXCL10 [40, 41]. Glucocorticoids increase the expression of dual-specificity phosphatase-1 (DUSP1) which targets c-Jun N-terminal kinase (JNK), extracellular-regulated kinase (ERK) and p38 MAPK pathways induced by inflammatory stimuli to provide feedback inhibition [42]. Glucocorticoids decrease the phosphorylation and activation of p38 MAPK via DUSP1-dependent regulation in macrophages and epithelial cells [43]. The induction of IRF1 and consequently CXCL10 by glucocorticoids is mediated by the increase of DUSP1 and therefore reduced MAPK activity [41]. In the context of such systems where MAPKs are involved in feedforward regulation, it has been suggested that reduced repression of MAPKs could provide superior repression of inflammatory genes [44].

To further understand the mechanisms of the combination effects observed, we sought to investigate the role p38 MAPK plays on GR phosphorylation at various sites. GR phosphorylation at S211 has an important role in the transcriptional activity of GR [45], by potentially inducing a functionally active folded conformation [46]. A lack of S211 phosphorylation has been linked to glucocorticoid resistance in human lymphoid cells [47]. However, Chang et al. [9] found that GR nuclear localisation was reduced in airway smooth muscle cells from patients with severe asthma compared with healthy controls, but this reduction was not due to altered S211 phosphorylation. In lymphoid cells, S211 is a substrate for p38 MAPK to enhance GR to stimulate transcription [13]. However in alveolar macrophages, exposure to nontypeable Haemophilus influenzae (NTHi) causes p38 MAPK-dependent GR phosphorylation at S226 but not S211, resulting in decreased GR function [18]. The role of p38 MAPK activity in the regulation of GR transactivation has also been shown in airway smooth muscle cells via regulation of GR phosphorylation at S203 and S211 [15]. These data highlight potential differences in cell type-specific and stimuli-specific GR phosphorylation.

Phosphorylation of GR S226 is involved with shuttling of GR out of the nucleus [48]. While GR ligands increase phosphorylation of GR at both S211 and S226, it is the relative level of S211 versus S226 phosphorylation which is important. Comparatively, higher phosphorylation at S211 relative to S226 correlates with GR nuclear localization and greater transcriptional activity and vice versa [17]. We show that, in bronchial epithelial cells, the effect of p38 MAPK is to modulate S226 rather than S211 phosphorylation, which may lead to increased nuclear export of GR.

Our observations regarding GR S226 phosphorylation are supported by data from a study using PBMCs from severe asthma patients, whereby a reduction in GR nuclear translocation was associated with increased GR S226 phosphorylation compared with healthy controls [19]. Furthermore, IL-2 and IL-4 caused p38 MAPK-dependent phosphorylation of GR at S226 in a human monocytic cell line (U937 cells) [19]. Additionally, p38 MAPK inhibition has been shown to reduce phosphorylation of GR S226 induced by NTHi in alveolar macrophages [18] or by IL-2/IL-4 in a myeloid cell line [19].

In summary, we have shown molecular crosstalk between p38 MAPK activation and GR function in human bronchial epithelial cells. p38 MAPK inhibitors used in combination with corticosteroids are known to have additive anti-inflammatory effects [8, 11], and we show here the potential for synergistic effects on cytokine production from bronchial epithelial cells. Combining corticosteroids and a p38 MAPK inhibitor may be an effective treatment option in patients with moderate-to-severe asthma, where there is evidence of increased p38 MAPK activation.

Acknowledgments DS and SL are supported by the National Institute for Health Research Manchester Biomedical Research Centre

Author contributions Conception and design, SL, JP, KG and DS; analysis and interpretation, SL, JP, KG, SM, JL, RG, CH and DS; drafting the manuscript for important intellectual content, SL and DS. All authors approved the final version of the manuscript prior to submission.

Funding information This work was partially funded by North West Lung Centre Charity. DS has received sponsorship to attend international meetings, honoraria for lecturing or attending advisory boards and research grants from various pharmaceutical companies including Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Genentech, GlaxoSmithKline, Glenmark, Johnson and Johnson, Merck, NAPP, Novartis, Pfizer, Skypharma, Takeda, Teva, Therevance and Verona. CH is an employee of Roche.

Compliance with ethical standards

Conflict of interest The authors declare that they have no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Price D, Fletcher M, van der Molen T (2014) Asthma control and management in 8,000 European patients: the REcognise asthma and LInk to symptoms and experience (REALISE) survey. NPJ Prim Care Respir Med 24:14009

2. Newton R, Holden NS (2007) Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor? Mol Pharmacol 72:799–809
Weigel NL, Moore NL (2007) Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Mol Endocrinol 21: 2311–2319

Weikum ER, Knuesel MT, Orlund EA, Yamamoto KR (2017) Glucocorticoid receptor control of transcription: precision and plasticity via allostery. Nat Rev Mol Cell Biol 18:159–174

Saccani S, Pantano S, Natoli G (2002) p38-dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol 3:69–75

Winzen R, Kracht M, Ritter B, Wilhelm A, Chen CY, Shyu AB, Muller M, Gaestel M, Resch K, Holtmann H (1999) The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J 18:4969–4980

Moretto N, Bertolini S, Iadicicco C, Marchini G, Kaur M, Volpi G, Patacchini R, Singh D, Facchinetti F, Chang PJ, Michaeloudes C, Shyu AB, Giembycz MA, Hoyer D, Insel PA, Lawrence AJ, Ayers SD, Khorasani N, Torrego A, Barnes PJ, Adcock I, Chung KF (2008) Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax 63:784–790

Liu W, Liang Q, Balzar S, Wenzel S, Gorska M, Alam R (2008) Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways. J Allergy Clin Immunol 121:893–902 e892

Southworth T, Plumb J, Gupta V, Pearson J, Rams I, Lehner MD, Miralpeix M, Singh D (2016) Anti-inflammatory potential of PI3Kdelta and JAK inhibitors in asthma patients. Respir Res 17:124

Curtis MJ, Bond RA, Spina D, Aho AM, Mrak M, Hye H, Chang PJ, Giembycz MA, Hoyer D, Insel PA, Izzo AA, Lawrence AJ, MacEwan D, Moon LD, Wonacott S, Weston AH, McGrath J (2015) Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmocol 172:3461–3471

Harbron C (2010) A flexible unified approach to the analysis of preclinical combination studies. Stat Med 29:1746–1756

Gisi U, Binder H, Rimbach G (1988) Synergistic interactions of fungicides with different modes of action. T Brit Mycol Soc 85: 299–306

Dendoncker K, Timmermans S, Van Looveren K, De Cauwer L, De Bosscher K, Libert C (2017) The nature of the GRE influences the screening for GR-activity enhancing modulators. PLoS One 12: e0181101

Dougherty EJ, Elinoff JM, Ferreyra GA, Hou A, Cai R, Sun J, Blaine KP, Wang S, Danner RL, Chen CY, Wenzel S, Gorska M, Alam R (2008) Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways. J Allergy Clin Immunol 121:893–902 e892

Armstrong J, Sargent C, Singh D (2009) Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages. Clin Exp Immunol 158:83–885 e875

Kent LM, Smyth LJ, Plumb J, Clayton CL, Fox SM, Ray DW, Farrow SN, Singh D (2009) Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor N-cyano-N’-(2-[(8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]amino)ethyl]guanidine (SB706504). J Pharmacol Exp Ther 328:458–468

Lea S, Plumb J, McTaffe H, Spencer D, Woodman P, Fox JC, Singh D (2013) The effect of PPAR-gamma ligands on in vitro and in vivo models of COPD. Eur Respir J. https://doi.org/10.1183/09031936.00187812

Mercado N, Hakim A, Kobayashi Y, Meah S, Usmani OS, Chung KF, Barnes PJ, Ito K (2012) Restoration of corticosteroid sensitivity by p38 mitogen activated protein kinase inhibition in peripheral blood mononuclear cells from severe asthma. PLoS One 7:e41582

Loxham M, Davies DE (2017) Phenotypic and genetic aspects of epithelial barrier function in asthmatic patients. J Allergy Clin Immunol 139:1736–1751

Chang PJ, Bhavsar PK, Michaeloudes C, Khorasani N, Chung KF (2012) Corticosteroid insensitivity of chemokine expression in airway smooth muscle of patients with severe asthma. J Allergy Clin Immunol 130:877–885 e875

Bhavsar P, Hew M, Khorasani N, Torrego A, Barnes PJ, Adcock I, Chung KF (2008) Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax 63:784–790

Armstrong J, Harbron C, Khan N, Booth G, Armstrong J, Singh D (2015) Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 mitogen-activated protein kinase (MAPK) inhibitor. Br J Clin Pharmacol 79:759–766

Chang PJ, Michaeloudes C, Zhu J, Shakh N, Baker J, Chung KF, Bhavsar PK (2015) Impaired nuclear translocation of the glucocorticoid receptor in corticosteroid-insensitive airway smooth muscle in severe asthma. Am J Respir Crit Care Med 191:54–62

Gaffey K, Reynolds S, Plumb J, Kaur M, Singh D (2013) Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs. Eur Respir J 42:28–41

Armstrong J, Harbron C, Lea S, Booth G, Cadden P, Wreggett KA, Singh D (2011) Synergistic effects of p38 mitogen-activated protein kinase inhibition with a corticosteroid in alveolar macrophages from patients with chronic obstructive pulmonary disease. J Pharmacol Exp Ther 338:732–740

Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM (2002) p38 mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 109:649–657

Miller AL, Webb MS, Copik AJ, Wang Y, Johnson BH, Kumar R, Thompson EB (2005) p38 mitogen-activated protein kinase (MAPK) is a key mediator in glucocorticoid-induced apoptosis of lymphoid cells: correlation between p38 MAPK activation and site-specific phosphorylation of the human glucocorticoid receptor at serine 211. Mol Endocrinol 19:1569–1583

Nader N, Ng SS, Lambrou GI, Pervanidou P, Wang Y, Chrousos GP, Kino T (2010) AMPK regulates metabolic actions of glucocorticoids by phosphorylating the glucocorticoid receptor through p38 MAPK. Mol Endocrinol 24:1748–1764

Bouazza B, Debban-Pavard M, Amrani Y, Isaacs L, D’Ottavio G, Amen K, Sun J, Blaine KP, Wang S, Danner RL (2016) Mineralocorticoid receptor (MR) trans-activation of inflammatory AP-1 signaling: dependence on DNA sequence, MR conformation, and Ap-1 family member expression. J Biol Chem 291:23628–23644

Delfino RJ, Boutstead JN, Fink C, Walker WH, Chung KF (2003) NF-kappaB and TNF-alpha stimulate androgen receptor expression in sertoli cells. Mol Cell Endocrinol 201:1–12

Malinen M, Niskanen EA, Kaikkonen MU, Palvimo JJ (2017) Crosstalk between androgen and pro-inflammatory signaling re-models androgen receptor and NF-kappaB cistrome to reprogram the prostate cancer cell transcriptome. Nucleic Acids Res 45:619–630

Armstrong J, Sargent C, Singh D (2009) Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages. Clin Exp Immunol 158:74–83

Kent LM, Smyth LJ, Hackett E, Claydon CL, Fox SM, Ray DW, Farrow SN, Singh D (2009) Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor N-cyano-N’-(2-[(8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]amino)ethyl]guanidine (SB706504). J Pharmacol Exp Ther 328:458–468
35. Southworth T, Metryka A, Lea S, Farrow S, Plumb J, Singh D (2012) IFN-gamma synergistically enhances LPS signalling in alveolar macrophages from COPD patients and controls by corticosteroid-resistant STAT1 activation. Br J Pharmacol 166: 2070–2083
36. Plumb JRL, Lea S, Banyard A, Blakley J, Ray D, Bizzi A, Volpi G, Facchinetti F, Singh D (2014) Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate. PLoS One
37. Woodman LB, Wan WYH, Milone R, Grace K, Sousa A, Williamson R, Brightling CE (2013) Synthetic response of stimulated respiratory epithelium: modulation by prednisolone and iKK2 inhibition. Chest 143:1656–1666
38. Charron CE, Russell P, Ito K, Lea S, Kizawa Y, Brindley C, Singh D (2017) RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-alpha and -gamma selectivity, suppresses COPD inflammation. Eur Respir J 50. https://doi.org/10.1183/13993003.00188-2017
39. Higham A, Karur P, Jackson N, Cunoosamy DM, Jansson P, Singh D (2018) Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells. Int J Chron Obstruct Pulmon Dis 13:1279–1288
40. Sakai A, Han J, Cato AC, Akira S, Li JD (2004) Glucocorticoids synergize with IL-1beta to induce TLR2 expression via MAP kinase Phosphatase-1-dependent dual inhibition of MAPK JNK and p38 in epithelial cells. BMC Mol Biol 5:2
41. Shah S, King EM, Mostafa MM, Altonsy MO, Newton R (2016) DUSP1 maintains IRF1 and leads to increased expression of IRF1-dependent genes: a MECHANISM PROMOTING GLUCOCORTICOID INSENSITIVITY. J Biol Chem 291: 21802–21816
42. Arthur JS, Ley SC (2013) Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 13:679–692
43. Clark AR, Martins JR, Tchen CR (2008) Role of dual specificity phosphatases in biological responses to glucocorticoids. J Biol Chem 283:25765–25769
44. Newton R, Shah S, Altonsy MO, Gerber AN (2017) Glucocorticoid and cytokine crosstalk: feedback, feedforward, and co-regulatory interactions determine repression or resistance. J Biol Chem 292: 7163–7172
45. Wang Z, Frederick J, Garabedian MJ (2002) Deciphering the phosphorylation “code” of the glucocorticoid receptor in vivo. J Biol Chem 277:26573–26580
46. Garza AM, Khan SH, Kumar R (2010) Site-specific phosphorylation induces functionally active conformation in the intrinsically disordered N-terminal activation function (AF1) domain of the glucocorticoid receptor. Mol Cell Biol 30:220–230
47. Miller AL, Garza AS, Johnson BH, Thompson EB (2007) Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells. Cancer Cell Int 7:3
48. Itoh M, Adachi M, Yasui H, Takekawa M, Tanaka H, Imai K (2002) Nuclear export of glucocorticoid receptor is enhanced by c-Jun N-terminal kinase-mediated phosphorylation. Mol Endocrinol 16: 2382–2392

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.